Sebra
SebraHealth is a rare disease clinical trial recruitment platform that identifies, qualifies, and connects patients with suitable research studies worldwide. The platform addresses the geographic mismatch between where rare disease patients live and where trials are conducted, with over 60% of patients residing in Asia-Pacific regions while only 14% of trial sites are located there. It was a finalist at the 2025 Harvard Rare Disease Hackathon.
- Healthcare Technology
- Digital Health
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Nearly 80% of clinical trials fail to meet enrollment targets on schedule, creating significant financial and development hurdles. Travel to specialized sites can be an "insurmountable barrier" for patients with severe rare diseases, and most trial sites are concentrated in North America and Europe despite the majority of rare disease patients living in Asia-Pacific and nearby regions.
Solution
SebraHealth provides a rare disease clinical trial recruitment platform that connects qualified patients with suitable research studies worldwide. The platform identifies and qualifies eligible patients, helping to bridge the geographic gap between where rare disease patients live and where trials are conducted. By streamlining the recruitment process, SebraHealth enables sponsors and research sites to meet enrollment targets more efficiently while expanding patient access to clinical trials that might otherwise be unreachable.
Target Audience
Primary customers are clinical trial sponsors, contract research organizations, and rare disease research sites seeking to accelerate patient recruitment and meet enrollment targets, particularly those looking to access underserved patient populations in Asia-Pacific regions.
Features
- Patient qualifying system designed for rare disease populations, including the 1 in 10 Americans with rare diseases of whom nearly half are children
- Global recruitment reach that addresses geographic disparities, targeting regions like South-East Asia and the Western Pacific where over 60% of rare disease patients reside but only ~14% of trial sites exist
- Strategic site matching capabilities that help overcome travel barriers for patients with severe conditions
- Recruitment infrastructure tailored to improve the ~80% of trials that currently miss enrollment deadlines
- Recognized as a finalist and received a 2025 Therapeutic Targets Honorable Mention at the Harvard Rare Disease Hackathon